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depleted compared to family or peers. In terms of social 
impact, symptoms lead to embarrassment and a sense of 
isolation, with patients concealing symptoms and/or their 
diagnosis. In turn, isolation was also linked with the lack 
of public and medical knowledge. In relation to emotional 
impact, anxiety was reported in a number of qualitative 
studies; patients were anxious about getting sick or when 
thinking about their future health. The burden of treatment 
and factors influencing adherence were also discussed in 
depth.
Conclusion Health-related quality of life decreases with 
age in patients with PCD. For all age groups, PCD was 
found to greatly impact physical, emotional, social func-
tioning, and treatment burden. More research is needed on 
the psychosocial impact of the illness, disease burden and 
its effect on quality of life.
Keywords Primary ciliary dyskinesia · Patient 
perspective · Health-related quality of life · Patient 
experience
Background
Primary ciliary dyskinesia (PCD) is a rare, inherited lung 
disease affecting cilia motility such that mucociliary clear-
ance is impaired. Individuals with PCD often present with 
unexplained neonatal symptoms such as neonatal cough, 
rhinitis transient tachypnoea, and pneumonia, often requir-
ing respiratory support [1–3]. Patients continue to have 
persistent sinopulmonary symptoms in infancy. Chronic 
and progressive chest symptoms persist throughout life 
and include daily wet cough and recurrent chest infections 
which almost consistently lead to bronchiectasis [4, 5]. 
By adulthood, bronchiectasis is present and some patients 
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Background Primary ciliary dyskinesia (PCD) is a rare 
genetic disorder characterised by progressive sinopulmo-
nary disease, with symptoms starting soon after birth. The 
aim of this study is to critically review, analyse, and syn-
thesise the literature in order to understand the experiences 
of patients with primary ciliary dyskinesia (PCD) and the 
impact on health-related quality of life.
Method MEDLINE, EBSCO, Cumulative Index to Nurs-
ing and Allied Health Literature (CINAHL), PsycINFO 
and EMBASE were searched according to the inclusion cri-
teria. A qualitative analysis of 14 studies was conducted.
Results Fourteen studies were included in the review, five 
with qualitative methodologies. Studies originated from the 
UK, USA, Italy, Denmark and Belgium, one study included 
a survey distributed internationally. Significant relation-
ships were found between age and worsening of respiratory 
symptoms, physical, and mental domains of health-related 
quality of life, with a greater decline compared with ref-
erence populations. Variations between the UK and Italy 
were found for health-related quality of life and its correla-
tion with time since diagnosis. PCD was found to have a 
physical impact in all age groups: patients found it difficult 
to keep up with others, and found energy levels were easily 
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develop respiratory failure [2]. Upper airway symptoms 
include rhinosinusitis and recurrent serous otitis media 
with hearing impairment [6]. Situs inversus is found in 
approximately 50% of cases and situs ambiguous is seen in 
approximately 10% of cases [6, 7].
Assessment on the prevalence, burden of disease, and 
prognosis of PCD patients is difficult to determine due to 
a lack of representative international data. Reported preva-
lence varies from 1:2000 to 1:40,000; this could reflect true 
variability or could be a result of poor access to diagnostic 
facilities in some areas and countries [8–10]. A European 
Respiratory Society (ERS) Task Force survey of 26 Euro-
pean countries found that PCD is both under-diagnosed and 
diagnosed late [8].
As in most orphan diseases, research has focused on 
describing the pathophysiological mechanisms of the ill-
ness and improving diagnostics. Few studies have exam-
ined the psychosocial impact of the illness, disease burden, 
and its effect on health-related quality of life. This was 
highlighted by McManus back in 2003 [11], where a sys-
tematic search found no studies reporting from the patient 
perspective on impact to daily functioning, or on mental 
health and well-being.
The overall aim of this study was to synthesise the 
results from both qualitative and quantitative studies which 
examine the psychosocial impact of PCD. Through this 
synthesis, we evaluated qualitative studies documenting the 
experiences and views of PCD patients, the impact of the 
condition on their daily lives, in addition to health-related 
quality of life and any influencing factors. We included all 
age groups (adults, children, adolescents) and parents of 
PCD children. The qualitative studies allowed us to identify 
the most salient themes among age groups through inter-
views and focus groups analysis. The quantitative studies 
allowed us to compare patient-reported outcome meas-
ures (PROMs) and factors influencing variability. Finally, 
through this synthesis, we assessed the quality of the stud-
ies and made recommendations on future research needs.
Method
Search strategy
The systematic review was conducted using the Preferred 
Reporting Items for Systematic Review and Meta-Analyses 
Approach (PRISMA) [12]. The following electronic data-
bases searched for papers published in the English language 
from inception until September 2015: MEDLINE–EBSCO, 
Cumulative Index to Nursing and Allied Health Literature 
(CINAHL), PsycINFO and EMBASE. Keywords and sub-
ject headings/MeSH terms searched in titles and abstracts 
using various combinations included: “ciliary dyskinesia, 
primary”, “ciliary motility disorder”, “Kartagener’s syn-
drome”, “primary ciliary dyskinesia”, “perspective”, 
“perception”, “knowledge”, “opinion”, “psychological”, 
“experience”, “attitude”, “impact”, “view”, “idea”, “qual-
ity of life”, “QOL”, “HRQL”, “patient report”, “belief”, and 
“awareness”.
Inclusion and exclusion criteria
Inclusion criteria were primary studies that reported on 
experiences and perspective of PCD patients of all age 
groups or where patients completed PROMSs as primary or 
secondary outcomes. Quantitative, qualitative, and mixed 
methodologies were considered equally. PROMs were 
operationalised as generic health-related quality of life 
questionnaires, e.g. Short Form-36 (SF-36), and disease-
specific health-related quality of life questionnaires, e.g. St. 
George’s Respiratory Questionnaire (SGRQ) and Leicester 
Cough Questionnaire (LCQ). Measures of psychological 
distress, e.g. Child Behaviour Checklist questionnaire and 
Parenting Stress Index–Short Form, were also included. 
Qualitative studies and mixed methods studies with a sig-
nificant qualitative component were considered for inclu-
sion if the number of participants was greater than one, and 
if sufficient methodological details and data were provided. 
Non-primary research articles (letters, commentaries, and 
reviews) were excluded.
Search outcome
The initial database search generated records from which 
articles were initially identified through screening of titles 
and abstracts as potentially relevant (LB and BR). Follow-
ing removal of duplicates, papers of full text were read by 
two authors (LB and BR) to determine eligibility for inclu-
sion. Discrepancies about whether a paper met the inclu-
sion criteria were discussed with a third author (JSL) and 
a final decision was based on consensus. References of the 
full text articles assessed for eligibility were hand-checked 
to identify further papers that satisfied selection criteria.
Data extraction and analysis
The following data from included papers were extracted: 
author, date and location of study, aim, sample, design and 
methods, data collection and analysis, and results.
Data from included studies were systematically extracted 
using a standardised tabulated form (Table  4) by LB and 
BR independently, and then discussed and combined. In 
order to address the aims of this review, data were extracted 
on the results from health-related quality of life measures 
and patient-reported outcome measures. For qualitative 
studies, extracted data were compared across studies and 
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grouped into themes to describe the issues pertinent to 
PCD patients.
Quality appraisal
Quality appraisals of data from both the qualitative and 
qualitative studies were independently assessed by LB and 
BR. The criteria for assessing the quality of quantitative 
studies as previously used by researchers [13–15] included 
study design, participants and recruitment, comparison 
group, number of participants, and quality of instrument 
used (Table 1). The total quality score ranged from 0 to 15 
with each of the five criteria being score from 0 to 3. Qual-
ity assessment on the qualitative studies was performed 




The initial database search generated 260 records from 
which 32 articles were initially identified through screen-
ing of titles and abstracts as potentially relevant (Fig. 1). 
Removal of duplicates resulted in 26 papers of full text. 
Fourteen papers were identified for inclusion, two of 
which were conference abstracts where the full results 
were not available. For two additional abstracts (manu-
scripts now published) [10, 17], the authors had access 
to study results. No further papers were identified where 
references of the full text articles were hand-checked.
Studies included samples from the UK [11, 18–20], 
Italy [21–24], Denmark [25], and Belgium [26, 27] with 
collaborative works including participants from the UK 
and North America [17, 28] and an international study 
including participants from 25 countries [10]. Six studies 
consisted of cross-sectional surveys, two of which com-
pared the PCD sample results with reference population 
norms [11, 20–22, 26, 27], one was a longitudinal sur-
vey given at two time points [23], three were case–con-
trol design including healthy samples for comparison [24, 
25]. Four used a qualitative approach [17–19, 28] and 
one used a mixed method approach [10]. Three of the UK 
studies [11, 19, 20] were carried out using the same study 
population. The two Belgian studies were also conducted 
on a shared sample. Sample sizes ranged from 5 to 270. 
Apart from one study, gender was reported and all con-
tained both male and female samples (Table 2).
Table 1  Criteria for rating methodological quality of quantitative studies
Adapted from previously reported studies [13–15]
Study parameter Rating Criteria
Study design 3 Longitudinal prospective design (explicitly stated)
2 Retrospective or mixed design (explicitly stated)
1 Cross-sectional (explicitly stated)
0 Survey or did not report
Participants and recruitment 3 (1) Description of the population, (2) eligibility of participants, (3) precise details of the recruitment 
process, (4) accounted for the number recruited, (5) loss to follow up
2 Minimal description of at least four criteria
1 Two criteria missing
0 More than two criteria missing
Comparison group 3 Healthy, age-appropriate comparison (i.e. adolescents/young people aged 13–25 years)
2 Reference sample
1 Other comparison group (i.e. adults)
0 No comparison group
Number of participants 3 n > 100
2 n = 50–100
1 n < 50
0 Did not report
Instruments used 3 Psychometrically sound report of instruments used
2 Some weak psychometric properties reported
1 Psychometric properties of instruments reported as inadequate for measuring HRQoL or IQ, physical 
functioning. etc
0 No psychometric properties reported
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Methodological quality
Quality appraisal of the quantitative studies points to defi-
cits, in particular to study design, and recruitment and 
inclusion of a comparison group (Table  3). Psychometric 
properties of the measures were cited in five of the quanti-
tative studies; however, the internal reliability of the meas-
ures, i.e. Cronbach’s alpha within the sample population, 
was not reported in any of the studies. The application of 
the measures was not clear for all studies. For some studies, 
measures used were not developed/adapted and validated 
specifically for younger children. Most studies were surveys 
(with one being longitudinal) and although it was apparent 
that these studies were cross-sectional, this was not stated 
explicitly in all. The study which ranked the highest had a 
score of 8 out of 15 points; this was a cross-sectional survey 
study where 78 patients completed a questionnaire which 
collected information on age of diagnosis, symptoms and 
likely PCD-specific problems in addition to disease-spe-
cific and general HRQoL (using the St. George’s Respira-
tory Questionnaire and the Medical Outcomes Study Short 
Form-36 (SF-36)). Use of the SF-36 allowed for scores to 
be compared with the healthy Italian population.
For the four qualitative studies, criteria of the COREQ-
32 item checklist are generally adhered to Table  4. The 
main deficits in reporting were the characteristics of the 
research team and the relationship between interviewee and 
interviewer, description of the coding tree, and the provi-
sion of feedback to the interviewee.
Methodologies of quantitative and qualitative studies
Six studies assessed health-related quality of life (HRQoL) 
in PCD patients. HRQoL measures are generic or disease-
specific. Disease-specific measures assess special states and 
concerns of different diagnostic groups and are important 
for the detection of small clinically important changes. The 
most commonly used disease-specific HRQoL measure in 
this review was the St. George’s Respiratory Questionnaire 
(SGRQ) for chronic obstructive pulmonary disease (n = 6). 
Other disease-specific outcome measures used included 
the HRQoL measure for cystic fibrosis (CFQ-R) (n = 1), a 
Fig. 1  PRISMA Flow Diagram 
for search to investigate PCD 
from the patients’ perspective
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HRQoL measure for sinonasal conditions: The Sino-Nasal 
Outcome Test (SNOT-22) (n = 1), and the Leicester Cough 
Questionnaire (LCQ) (n = 1). To assess the impact of 
PCD on HRQoL, related to mental health and well-being, 
the Medical Outcomes Study Short Form 36 (SF-36) was 
used in five of the studies. Other patient-reported meas-
ures that measured outcomes other than HRQoL included 
the Wechsler Intelligence Scale for Children, the Child 
Behaviour Checklist questionnaire, the Parenting Stress 
Index–Short Form and the Self-reported Physical Activ-
ity Measure. One study included a questionnaire measur-
ing Stigma [20]. This was developed by the author and 
stigma was assessed by the patient’s response to 11 items 
on embarrassment about symptoms, feeling a nuisance to 
friends or family, concealment of condition, etc. Four of 
the studies were cross-sectional, single-occasion, single-
centred studies. One study was a cross-sectional, single-
occasion, single-centred case–control study, and one was 
a cross-sectional, longitudinal, single-centred study with 
measures repeated after 1 year.
Main themes
Factors influencing health‑related quality of life
In a cross-sectional UK survey [11], a slight decline in 
HRQoL was found for all three domains of the SGRQ 
(Activity, Impacts and Symptoms) until the age of 25 years 
after which a more rapid decline occurred. The physical 
component score of the SF-36 also showed a continual 
decline with age so that by the age of 40 onwards, the 
health status of PCD patients was one and a half standard 
deviations below the population mean. In contrast, the men-
tal component score also declined with age however the 
declining health status broadly parallels that found in the 
general population as a whole, and was, at the most, one-
third to one-half a standard deviation below the population 
norms. Age was also an important factor in an Italian cross-
sectional survey study [21], where all three subscales of the 
SGRQ and the physical and mental component scores of 
the SF-36 declined significantly greater than norms for the 
corresponding Italian population. These declines, however, 
were found to be earlier in age than those reported in the 
UK study [11], where deterioration mainly occurred prior 
to and during adolescence. In the UK study, little abnor-
mality was found for the childhood and adolescence study 
population when compared to standard measures of the 
SF-36.
Both studies found that patients with an earlier diagnosis 
had better scores for the SGRQ Impact and Activity sub-
scales, suggesting the importance of early medical inter-
vention for HRQoL. The Italian group found a clear major-
ity of patients (71.8%) considering their quality of life 
significantly or slightly improved after diagnosis; however, 
there remained a progressive worsening of the disease over 
time. This was in contrast to the UK group who reported 
stable scores for patients after diagnosis.
Physical impact
Ten studies addressed the impact of PCD on physical func-
tioning [10, 11, 17, 18, 20–23, 25, 28]. The physical impact 
of PCD was reported by children, teenagers, and their par-
ents in a qualitative study using phenomenological analy-
sis methods [18]. Coughing was regularly mentioned by 
all participants in their accounts of daily activities, as was 
the impact of their cough on activities when both well and 
unwell. Symptomatic relief of chest symptoms was reported 
Table 3  Summary of the 
quality of the data and studies 
contributing to the quantitative 
studies included in this 
systematic review
Scoring was according to Criteria for Rating Methodological Quality of Quantitative Studies adapted from 
previous studies [13–15]
a Same UK sample n
b Same Belgian sample









Behan et al. [10], International 0 2 0 3 0 5
Carotenuto et al. [24], Italy 0 0 3 1 2 6
Madsen et al. [25], Denmark 1 2 3 1 0 7
Maglione et al. [23], Italy 3 0 0 1 0 4
McManus et al. [20],  UKa 0 1 0 2 2 5
McManus et al. [11],  UKa 0 1 2 2 2 7
Mirra et al. [22] 1 0 0 1 2 4
Pifferi et al. [21], Italy 1 1 2 2 2 8
Taelman et al. [27],  Belgiumb 0 0 0 1 0 1
Taelman et al. [26],  Belgiumb 0 1 0 1 0 2
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as leading to a sense of freedom at being able to undertake 
activities without restrictions. Patients reported feeling lim-
ited in their ability to keep up with peers because of cough-
ing, breathlessness, fatigue and low energy levels. Similar 
themes arose in two collaborative qualitative studies, which 
included interviews with patients from the UK and North 
America [17, 28]. Children and teenagers reported they 
became tired quickly when engaging in physical exercise 
and needed to request more breaks than their peers. This 
theme relating to the physical impact of PCD was also 
found in adult interviewees, where patients reported not 
being able to keep up with others when walking or exercis-
ing (Box 1).
In a quantitative study, 10% of patients were found to 
be moderately-to-highly limited by respiratory symptoms 
in everyday activities, and 52% of cases had moderate-to-
severe limitations in performing vigorous activities [22]. 
This was in contrast to a Dutch study where 34% of patients 
Table 4  Summary of 
completeness of reporting for 
the qualitative studies included 
in this systematic review using 
the Consolidated Criteria for 
Reporting Qualitative Health 
Research [16]
Reporting criteria No (%) n = 5 References of stud-
ies reporting each 
criterion
Characteristic of research team
 Interviewer/facilitator identified 4 (80%) [23, 24, 35, 36]
 Credentials 2 (40%) [23, 35]
 Occupation 2 (40%) [23, 35]
 Gender 0 (0%) –
 Experience and training 2 (40%) [23, 35]
Relationship with participants
 Participation knowledge of the interviewer 2 (40%) [23, 35]
 Interviewer characteristics 3 (60%) [23, 24, 35]
 Methodological orientation and theory 5 (100%) [23, 24, 34–36]
Participant selection
 Sampling method (for example, snowball or purposive) 5 (100%) [23, 24, 34–36]
 Method of approach 5 (100%) [23, 24, 34–36]
 Sample size 5 (100%) [23, 24, 34–36]
 Non-participation 2 (40%) [23, 24]
Setting
 Setting of data collection 4 (80%) [23, 34–36]
 Presence of non-participants 1 (20%) [23]
 Description of sample 5 (100%) [23, 24, 34–36]
Data collection
 Interview guide 5 (100%) [23, 24, 34–36]
 Repeat interviews 1 (20%) [23]
 Audio/visual recording 5 (100%) [23, 24, 34–36]
 Field notes 3 (60%) [23, 24, 36]
 Duration 2 (40%) [23, 24]
 Data saturation 4 (80%) [23, 34–36]
 Transcripts returned to participant 0 (0%) –
Data analysis
 Number of data coders 5 (100%) [23, 24, 34–36]
 Description of the coding tree 0 (0%) –
 Derivation of themes 5 (100%) [23, 24, 34–36]
 Protocol for data preparation and transcription 5 (100%) [23, 24, 34–36]
 Software 4 (80%) [23, 34–36]
 Participants’ feedback or member checking 3 (60%) [23, 34, 35]
Reporting
 Participant quotations presented 5 (100%) [23, 24, 34–36]
 Data and findings consistent 5 (100%) [23, 24, 34–36]
 Clarity of major themes 5 (100%) [23, 24, 34–36]
 Clarity of minor themes 5 (100%) [23, 24, 34–36]
 Qual Life Res
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reported being moderately-to-highly limited by sinopul-
monary symptoms in activities of everyday life, and 39% 
reported moderate-to-severe limitations in performing vig-
orous activities. None of the healthy controls reported any 
limitations in physical abilities.
As reported previously, a continual decline accord-
ing to age in scores on the physical domain of the SF-36 
reflected a moderate degree of morbidity on normal physi-
cal functioning which is progressive across the lifespan 
[11]. Cough, on almost all days of the week in the last 12 
months, was the most frequently reported symptom (48.7% 
of patients) regardless of age, together with excessive spu-
tum (57.7% of patients) [21].
Emotional impact: frustration, anxiety and stress
The emotional impact was explored in depth in three of 
the five the qualitative studies [17, 18, 28]. Interviews in 
the UK and North America explored the emotional impact 
of PCD in all age groups [17, 28]. In the paediatric group, 
frustration relating to treatment burden was a prominent 
theme. Children and adolescents reported feeling frustrated 
about getting sick regularly and about the chronic nature of 
their symptoms. In addition, a sense of unfairness and sad-
ness about having this condition was reported. A UK quali-
tative study [18] found that children and teenagers became 
anxious when thinking about their health in the future. The 
positive changes which had arisen from their diagnosis and 
effective health care, while appreciated, induced a level of 
doubt and anxiety as to how these improvements could be 
sustained. Such feelings of anxiety were also found in a 
series of interviews with adult patients [28]. This was espe-
cially the case when thinking about their future and future 
health. They reported feeling anxious about being able to 
conceive children as well as being well enough to care for 
their family (Box 2).
Carotenuto et  al. conducted a behavioural and psycho-
logical evaluation of children with PCD and compared the 
results to healthy children [24]. The findings showed no 
clinically relevant scores for both healthy and PCD groups. 
However, higher scores were found in the PCD group 
for factors such as withdrawnness, somatic complaints, 
anxious/depressed items, attention span, and internalis-
ing problems items (p < 0.05). This study also found that 
total stress levels [assessed through the parenting stress 
index–short form (PSI/SF)] in mothers were significantly 
higher in the PCD group than in mothers of healthy con-
trols (p < 0.01), and that all PCD mothers had high levels 
of stress.
Social impact: Stigma, embarrassment and concealment
In the qualitative studies, symptoms such as coughing, spu-
tum production, and ear drainage were reported as caus-
ing embarrassment among paediatric patients [17, 18, 28]. 
Acceptance of coughing was found to be variable among 
participants and depended on severity. There was also a 
sense of revulsion from coughing up sputum. Symptom 
relief led to patients feeling ‘normal’ [18] (Box  3), para-
doxically a reluctance to adhere to treatments was also 
attributed to wanting to feel normal [26, 27]. Adult patients 
also reported embarrassment [19], with patients conceal-
ing symptoms such as coughing and blowing their nose. 
In a study assessing stigma (measured using a question-
naire developed for this study) [20], 75% of the sample 
agreed that their coughing or breathing was embarrassing 
Box 1  Patient experiences of the physical impact of PCD
A: “I go running again and then cough a bit and then I’ll stop” Child [18]
B: “I had to tell the group not to worry because I start huffing and spluttering as I’m walking.” Adult [28]
“My air goes out because I’m running and I can’t speak and then I’m not speaking and sometimes my air goes down a bit and then I can’t, and 
then I just can’t, I can’t, I can’t take it.” Child [18]
“…if he’s playing in school and …he needs to run around, then he gets more tired than other kids and they’re still running around and he’s stop-
ping.” Parent [17]
Box 2  Patient experiences of the emotional impact of PCD
A: “I was sick on and off…it’s just frustration. Because there’s no cure.” Adolescent [17]
B: “Sometimes, when he sees his friends running around and he can’t tag them, then he feels like why do I have PCD?” Parent [17]
C: “It…just wastes all of my energy, it makes me feel like I don’t want to wake up in the mornings” Child [17]
D: “I’m so frustrated with this illness, I just want it to go away, but, unfortunately, that’s how I have to live.” Adult [28]
E: “…if you go to the doctor [and] you’re feeling pretty good and you know your numbers are not good; that can be a big cause of anxiety.” 
Adult [28]
F: “Finding out that I possibly can’t have kids; that are when it started to panic me a little bit.” Adult [28]
G: “I’m still very uncertain if I ever wanna have children because I don’t know how me having this illness will affect them.” Adult [28]
Qual Life Res 
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in public. It also found that stigma correlated with symp-
toms and impact of illness from the SGRQ but not with 
activities. It also correlated with the mental health compo-
nent scores of the SF-36 but not for the physical component 
scores.
Paediatric patients were found to be reluctant to share 
their PCD diagnosis with teachers and peers or even to talk 
about their condition at home [18]. In a separate UK study 
of patient ≥10 years, 45% of patients agreed in a study-spe-
cific questionnaire that they have sometimes felt they had to 
hide their condition from other people [20]. Following on 
from this, a qualitative study [19] found that some patients 
felt frustrated by lack of knowledge of PCD in the general 
public. While some interviewees were keen to educate 
others and were open to discuss their illness, others were 
more censored, and avoided describing their symptoms. 
The likelihood of disclosure may be dependent on context, 
since some patients felt under pressure to disclose their 
diagnosis, for example, to teachers or work managers on 
an account of needing time off when ill. There were other 
patients who reported avoiding open disclosure, particu-
larly when at school (Box 3).
Lack of PCD awareness among medical practitioners
A mixed method study [10] reported the accounts of 20 
adult patients and parents of children and teenagers from 
nine different countries on their experience of being diag-
nosed with PCD or going through the diagnostic process. 
The most prominent theme reported among interviewees 
was a frustration with the lack of PCD awareness among 
medical practitioners, manifesting initially in the failure 
of general practitioners (GPs) to refer them for PCD diag-
nostic testing. This was also found in a UK-based qualita-
tive study, using grounded theory analytical methods [19] 
where failure to diagnosis PCD until later in life left some 
patients feeling distrustful of medical care. Themes such as 
distrust in GPs, difficulty getting antibiotics, and isolation 
due to poor communication between GPs and specialists 
were reported by both studies [10, 19].
Treatment adherence and treatment burden
Two abstracts [26, 27] from a survey using the same sam-
ple but presenting separate results examined treatment 
adherence. A range in the levels of agreement was found 
between self-reported and prescribed treatment, ranging 
from 39% for eardrops, to 71% for antibiotics, and 89% for 
physiotherapy. Barriers to completing treatments included 
being too busy, forgetting about treatments, family issues, 
and treatments taking too much time. For adolescents, 57% 
agreed that their PCD team do not understand how difficult 
it is to follow treatments, and 43% felt that having to follow 
the PCD treatments meant less freedom in life. The diffi-
culty of fitting treatments in on a daily basis was reported 
by 12/20 adolescents interviewed across the UK and North 
America [17]. Interviews with adult PCD patients also 
reported the challenges of completing their treatments [10, 
28] (Box 4).
There was agreement among parents of children with 
PCD (76%) that barriers to completing treatments meant 
less freedom in life [26]. Parents expressed how other com-
mitments, such as siblings and employment, could limit 
their ability to complete daily treatments [17, 18] (Box 4).
Box 3  Patient experiences of the emotional impact of PCD
A: “actually coughing up mucus isn’t a very nice thing. It’s not, it’s quite a sort of...frowned on in society kind of thing isn’t it so I kind of, yeah, 
I don’t think it’s very nice, sort of, to do it in front of people” Adult [19]
B: ‘Sometimes I raise my hand and then say, ‘I have to blow my nose.’ And then I go in the bathroom…and shut the door because I don’t want 
anyone to hear me [because] it’s embarrassing.” Child [17]
C: “I feel like I’m being judged by other people because I constantly sniff and…cough.” Teenager (Dell)
D: “If she has a speech problem or…coughing constantly…when they’re in school, it might become embarrassing.” Parent [17]
E: When I cough. .. it feel a bit more, erm.. . like I’ve got PCD, but when I don’t cough I just feel normal. Child [18]
Box 4  Patient’s experiences of treatment burden
A: “I think it just requires more planning. I need to wake up earlier or start getting ready for bed earlier, I need to come home from work and do 
this; it’s just more planning.” Adult [28]
B: “It was a bit of a shock…. I was probably in my mid-thirties then, to suddenly be told, right, you’ve got to do 20 minutes of physio twice a 
day, you’ve got to take this blue puffer, and the brown puffer… as soon as you get a chest infection you’ve got to take really strong antibiotics, I 
rebelled against that” Adult [10]
C: “She was sick every month. Once we had a diagnosis… she gets sick, but not as severe as… before.” Parent [10]
D: Definitely milder…you know we have a treatment plan and even when she starts to get sick; those medications are changed so we tend to 
catch that right away rather than after that.” Adult [10]
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Patients did report that following a PCD diagnosis, 
treatments could reduce symptoms providing sensations 
of relief. There was a subjective perception of physi-
otherapy treatments, corresponding to fluctuating levels 
of motivation. There was also a variance different lev-
els of PCD health literacy knowledge in the preventative 
nature of physiotherapy among children and teenagers 
[18]. In a cross-sectional survey study [26], 86% agreed 
that they had difficulty complying with treatments because 
they made them feel physically worse; however, 96% of 
patients acknowledged their health would decline without 
treatments. In the mixed methods study by Behan et al., a 
study-specific survey [10] found a significantly higher level 
of agreement that health had improved since diagnosis 
(p = 0.041) in those diagnosed in childhood (0–12 years) 
compared to those who were diagnosed in adolescences/
adulthood (>13 years).
Discussion
This systematic review identified 14 studies focussing on 
the perspectives, opinions, and attitudes of patient with 
PCD. Most of the quantitative studies consisted of small 
cross-section surveys and the methodological quality of 
these studies was generally low (Table 3). While the quali-
tative studies provided a deeper insight into the patient 
experience, only a small number of these studies exist, and 
mostly include patients from the UK and North America. 
Notwithstanding these weaknesses, the evidence assembled 
from the studies makes an important contribution to under-
standing the PCD patient experience and associated influ-
ences relating to quality of life.
Two cross-sectional studies suggested a correlation 
between age and worsening of respiratory symptoms, gen-
eral physical and mental quality of life. Within these two 
studies, variances exist with Pifferi reporting an early 
decline in HRQoL and McManus reporting little abnor-
mality in standard measures of SF-36 during childhood 
and adolescence. Also the variances between the two stud-
ies could be due to differences in the age of participants 
involved or a result of their limited sample size. It could 
also be due to cultural differences between the countries 
(UK and Italy), access to specialist diagnostic, and manage-
ment services or treatment adherence may also account for 
differences. Caution must be exercised in the interpretation 
of these findings. Cross-sectional studies do not take into 
account confounding factors such as differences between 
adult and child participants and experience which may 
affect changes over time, i.e. diet, tobacco smoke exposure, 
etc. The progressive nature of PCD and the deterioration of 
health have been described in other studies through physi-
ological methods such as spirometry [5]. Werner et al. [29] 
have shown the percentage-predicted forced expiratory 
volume in 1  s (FEV1% pred) values versus age exhibited 
a mean annual decline of 0.59%. The results show interest-
ing trends and however highlight the need for large longi-
tudinal international studies before more reliable conclu-
sions can be made. The Genetic Disorders of Mucociliary 
Clearance Consortium (GDMCC), the iPCD cohort and the 
BESTCILIA registry are examples of ongoing large-scale 
studies that will contribute to this aim.
The physical impact of PCD was a prominent theme 
in both the qualitative and quantitative studies. This was 
defined by the most prominent feature of this illness: 
coughing. Coughing was regularly mentioned by inter-
viewees of all age groups [17, 18, 28]. It was the most fre-
quently reported symptom in a survey of 78 participants, 
where 48.7% reported having to cough nearly all days of 
the week for the past 12 months [21]. Persistent presence 
of cough was found to be far less prevalent than that in 
other studies [10, 30] where it was found to be as high as 
93–100%. This could be as a result of the way in which the 
question was phrased or the method of data collection used, 
i.e. patient reporting at home or reporting to a clinician in 
a hospital setting. Severity of symptoms might also reflect 
different data collection points, with patients on their first 
referral appointment prior to diagnosis and commencement 
of treatments exhibiting more severe symptoms. The physi-
cal impact of PCD was expressed by patients in the qualita-
tive studies, as not being able to keep up with other family 
members and peers due to fatigue [17, 18, 28].
Questionnaire findings [24] showed that PCD children 
were more likely to be withdrawn, experience anxiety or 
depression, and internalise more problems than the healthy 
population. PCD was found to affect the parent also with 
significantly higher stress being reported in mothers of 
children with PCD. No other PCD study reports on these 
factors; however, studies in children and parents with 
cystic fibrosis have also reported elevated levels of depres-
sion, stress and anxiety compared to healthy populations 
[31, 32]. The synthesis of the qualitative studies allows 
the researcher to conclude possible reasons for this. PCD 
impacts greatly on the emotional functioning of patients in 
all age groups. Children described the frustration of hav-
ing constant symptoms and recurrently getting sick. Patient 
anxiety was expressed, especially when thinking about the 
near and distant future. Children reported feeling worried 
about their health and of getting sick. A sense of sadness 
was reported because of their awareness of being differ-
ent from other children. There is a need for further explo-
ration on how PCD causes stress in developmental ages 
and the psychological effects of PCD on intra-familiar 
relationships.
Concealing PCD symptoms such as cough and blowing 
nose in public were reported across the qualitative studies 
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[17–19, 28]. Embarrassment was mostly from coughing 
and producing sputum in public; however, ear drainage was 
also reported as an embarrassing symptom in one of the 
paediatric studies [17]. The stigma questionnaire (which 
included items on embarrassment from symptoms and 
concealment) correlated with mental health and the social 
impact of symptoms. Although the impact of PCD on 
school functioning was expressed by patients [17, 28], no 
differences in educational level or IQ were found between 
PCD children and healthy children. School functioning 
instead could be related to patients’ reluctance to disclose 
their PCD diagnosis with teachers and peers. Such conceal-
ment of symptoms and illness disclosure has been reported 
across chronic illness [33–36]. Results from a cystic fibro-
sis study [36] found that patients were more likely to dis-
close to romantic partners and close friends than to casual 
friends, bosses, or co-workers, and disclosure was associ-
ated with higher social support, social functioning, and 
medication adherence self-efficacy.
Poor adherence to treatments can often be a conscious 
decision in PCD; however, it can be the result of not mak-
ing any decisions at all, e.g. worry about having PCD could 
lead to attempts to avoid thinking about it. Poor adherence 
however is likely to lead to raised anxiety about the conse-
quences, which often leads to attempts by the individual to 
minimise the risks [37]. This process is known as cogni-
tive dissonance which refers to the widespread observation 
that in any situation where people who feel uncomfortable 
about a choice they have made, also hold a strong desire 
to resolve this discomfort. Its resolution is central to moti-
vating patients to change [38]. Cognitive dissonance has 
been reported in cystic fibrosis; however, further investi-
gation is needed in PCD. This literature synthesis did find 
that symptom relief led to patients feeling ‘normal’ [18] 
but paradoxically, there was a reluctance to adhere to treat-
ments which was also attributed to wanting to feel normal 
[26, 27]. Furthermore, in a cross-sectional survey study 
[26], 85.7% agreed that they had difficulty complying with 
treatments because they made them feel physically worse; 
however, 96% of patients acknowledged their health would 
decline without treatments. There was also a variance in the 
levels of PCD health literacy and in the knowledge of the 
preventative nature of physiotherapy among children and 
teenagers [18]. The perception of physiotherapy treatments, 
which corresponding to fluctuating levels of motivation, 
highlighted the need for patient centeredness and personal-
ised medicine.
Limitations
The review has limitations. Papers included were lim-
ited to those published in the English language. It is pos-
sible that there are relevant studies published in other 
languages. Overall the evidence of this review is based on 
a small number of heterogeneous studies (n = 14) that are 
limited in size. The quality assessment of the quantitative 
studies revealed them to be of low quality with scores no 
greater than 8 points. Until recently, no disease-specific 
age-appropriate HRQoL measures were available for 
PCD patients [17, 28] and to date, studies have used gen-
eral HRQoL tools such as the SF-36 and disease-specific 
tools for cystic fibrosis and COPD. These studies have 
also included child participants to complete measures 
that are not age appropriate without psychometric valida-
tion. Studies have included results where young children 
had help from a parent to complete these measures which 
may lead to bias [34]. Only one of the studies performed 
analyses with and without the children who needed help 
completing the questionnaire. In addition, limited psycho-
metric data were presented on the validity of the HRQoL 
used, with some studies reporting validity but never for 
all of the scales. As with any review, the quality of stud-
ies included can only be assessed by what was reported 
in the final manuscript, e.g. missing information on any 
of the adopted criterion might reflect unclear reporting as 
opposed to a limitation in study design.
Recommendations
To date, no medications to treat PCD have been approved 
by regulatory bodies [30] and current physiological out-
come measures such as spirometry, chest computed 
tomography, and lung clearance index have been reported 
to have limitations in terms of their sensitivity and feasi-
bility for evaluating new therapies or disease progression 
[4, 39–41]. These physiological measures also do not 
reflect the impact of the disease on patients’ daily symp-
toms or functioning (e.g. physical, respiratory, social) as 
required by the Food and Drug Administration [42] and 
the European Medicines Agency [43, 44]. This study has 
highlighted the need for large multi-national and longitu-
dinal studies to be conducted using PCD-specific health-
related quality of life measures (QOL-PCD) [28]. Stud-
ies are underway and QOL-PCD has been developed, 
validated [45] and translated comprehensively into six 
European languages. These tools have been included in 
the first international RCT azithromycin study [29]. The 
measures are also being included in an international PCD 
registry developed as part of the BESTCILIA FP7 study, 
providing an international platform to systematically col-
lect data on incidence, clinical presentation, treatment, 
and disease course. Qualitative studies that reflect dif-
ferent ethnicities and cultures are important and neces-
sary to establish the needs and opinions specific to these 
groups.
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Conclusion
The findings of this review indicate the physical impact, 
emotional and stigmatising impact of PCD. They high-
light the need for well-designed, quantitative studies 
using PCD-specific health-related quality of life meas-
ures to accurately determine the factors that impact PCD. 
There is also a need for the experience of patients to be 
further examined across ethnicities to evaluate various 
nuances between cultures. This will lead to better care, 
management, and outcomes for PCD patients.
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